Somewhat Positive Press Coverage Somewhat Unlikely to Impact Alliqua BioMedical (ALQA) Share Price

News stories about Alliqua BioMedical (NASDAQ:ALQA) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alliqua BioMedical earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.8786044191875 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Separately, ValuEngine upgraded Alliqua BioMedical from a “sell” rating to a “hold” rating in a report on Thursday, March 1st.

Alliqua BioMedical traded up $0.01, reaching $2.31, during midday trading on Tuesday, Marketbeat Ratings reports. The stock had a trading volume of 389 shares, compared to its average volume of 76,418. The firm has a market capitalization of $11.01 million, a P/E ratio of -0.36 and a beta of 0.94. Alliqua BioMedical has a 52-week low of $2.31 and a 52-week high of $2.32.

About Alliqua BioMedical

Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.

Insider Buying and Selling by Quarter for Alliqua BioMedical (NASDAQ:ALQA)

Receive News & Ratings for Alliqua BioMedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply